ProQuad is a combined attenuated live virus vaccine containing measles, mumps, rubella, and varicella viruses.
ProQuad is indicated for simultaneous vaccination against measles, mumps, rubella, and varicella in children 12 months through 12 years of age.
ProQuad may be used in children 12 months through 12 years of age if a second dose of measles, mumps and rubella vaccine is to be administered.
Published Studies Related to Proquad (Measles, Mumps, Rubella, Varicella Virus Vaccine Live)
Comparison of the safety and immunogenicity of a refrigerator-stable versus a frozen formulation of ProQuad (measles, mumps, rubella, and varicella virus vaccine live). [2007.06]
OBJECTIVE: A refrigerator-stable formulation of ProQuad has been developed to expand the utility of ProQuad to areas in which maintenance of a frozen cold chain (-15 degrees C or colder) during storage and transport may not be feasible. The objective of this study was to demonstrate that the immunogenicity and safety profiles of a refrigerator-stable formulation of ProQuad are similar to the recently licensed frozen formulation... CONCLUSIONS: The refrigerator-stable formulation of ProQuad is generally well tolerated, highly immunogenic, and noninferior in terms of postvaccination antibody responses. This refrigerator-stable formulation may improve ease of vaccine administration, increase use of the vaccine throughout the world because of its improved storage conditions, and replace the frozen formulation of ProQuad or any dose of M-M-RII and Varivax in routine practice.
Use of combination measles, mumps, rubella, and varicella vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). [2010.05.07]
This report presents new recommendations adopted in June 2009 by CDC's Advisory Committee on Immunization Practices (ACIP) regarding use of the combination measles, mumps, rubella, and varicella vaccine (MMRV, ProQuad, Merck & Co., Inc.). MMRV vaccine was licensed in the United States in September 2005 and may be used instead of measles, mumps, rubella vaccine (MMR, M-M-RII, Merck & Co., Inc.) and varicella vaccine (VARIVAX, Merck & Co., Inc.) to implement the recommended 2-dose vaccine schedule for prevention of measles, mumps, rubella, and varicella among children aged 12 months-12 years.
Efficacy and safety of measles, mumps, rubella and varicella live viral vaccines in transplant recipients receiving immunosuppressive drugs. [2008.11]
CONCLUSION: There are insufficient published data to derive evidence-based guidelines for use of live viral vaccines in transplant recipients on immunosuppression but preliminary data on efficacy and safety suggest that the use of these live viral vaccines in transplant recipients still on immunosuppression could be a reasonable strategy.
[Priorix Tetra: a new combined vaccine against measles, rubella, mumps and varicella] [2008.08]
Varicella is an infectious disease caused by a virus of the herpes virus family (VZV) affecting predominantly the pediatric age. Varicella is considered a mild disease, but in some cases, mainly in immunocompromised subjects, it can evolve towards complicated cases, even fatal.This review summarizes the epidemiology of measles, mumps, rubella and varicella in Italy, encompassing the rationale for the introduction of varicella vaccination and describes the immunological, clinical and safety profile of Priorix Tetra.
A combination vaccine against measles, mumps, rubella and varicella. [2008.04]
A new combination vaccine against measles, mumps, rubella and varicella (MMRV) from GlaxoSmithKline Biologicals has recently been approved in Europe. It combines the components from two well-established, live, attenuated vaccines against measles, mumps and rubella.
Clinical Trials Related to Proquad (Measles, Mumps, Rubella, Varicella Virus Vaccine Live)
Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 3, 4 and 12 Months (V419-007) [Recruiting]
This study will determine whether subjects who receive V419 at 2, 3, 4, and 12 months of age
have an acceptable immune response to the vaccine. The study will also determine whether the
immune response to V419 is similar to that of subjects who receive a licensed vaccine
Comparison of GSK Measles-mumps-rubella-varicella (MMRV) Vaccine Versus PriorixTM [Not yet recruiting]
The purpose of this study is to assess non-inferiority of two different vaccination regimens
using GSK Biological's MMRV vaccine (two doses at 9 and 15 months) or Priorixâ„¢ (9 months)
and one dose of MMRV vaccine (15 months) to the current standard of care which is Priorixâ„¢
administered at 9 months of age followed by concomitant administration of Priorixâ„¢ with
Varilrixâ„¢ at 15 months of age in a measles endemic environment such as India.
Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy Toddlers [Recruiting]
Safety immune response of Novartis MenACWY conjugate vaccine when given to healthy toddlers
Immunogenicity and Safety of Boostrix Polio Vaccine as a Booster Dose in 5 to 6-year-old Children. [Recruiting]
This phase 3b study will compare the immunogenicity and reactogenicity of the dTpa-IPV
vaccine to that of a DTPa-IPV vaccine when administered as a booster dose in healthy
children 5-6 years of age who have received three primary vaccination doses of DTPa-based
vaccine according to the "3-5-11" month schedule recommended in Italy.
In this study, MMRV vaccine will also be co-administered to all children.
Page last updated: 2010-10-05